GlaxoSmithKline (GSK) Stock Rating Upgraded by Beaufort Securities

GlaxoSmithKline (LON:GSK) was upgraded by research analysts at Beaufort Securities to a “buy” rating in a research report issued on Thursday. The brokerage currently has a GBX 1,500 ($21.03) target price on the stock, up from their prior target price of GBX 1,450 ($20.33). Beaufort Securities’ price target indicates a potential upside of 16.19% from the company’s previous close.

Several other research analysts also recently weighed in on the stock. Liberum Capital reissued a “buy” rating and issued a GBX 1,760 ($24.68) target price on shares of GlaxoSmithKline in a research note on Wednesday, October 25th. UBS Group set a GBX 1,550 ($21.73) target price on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Thursday. Credit Suisse Group set a GBX 1,300 ($18.23) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday. Societe Generale reissued a “sell” rating on shares of GlaxoSmithKline in a research note on Thursday, November 9th. Finally, Morgan Stanley set a GBX 1,600 ($22.43) target price on shares of GlaxoSmithKline and gave the company a “sell” rating in a research note on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of GBX 1,541.36 ($21.61).

GlaxoSmithKline (LON:GSK) traded down GBX 12.80 ($0.18) during trading hours on Thursday, hitting GBX 1,291 ($18.10). The stock had a trading volume of 11,680,000 shares, compared to its average volume of 9,480,000. The firm has a market cap of $64,010.00 and a P/E ratio of 4,164.52. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.32) and a fifty-two week high of GBX 1,724.50 ($24.18).

In other news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Also, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were purchased at an average price of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Insiders have bought a total of 581 shares of company stock valued at $743,284 in the last quarter.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Stock Rating Upgraded by Beaufort Securities” was published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/11/glaxosmithkline-gsk-stock-rating-upgraded-by-beaufort-securities.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply